TICKERNOMICS Sign up
Last Update: 2024-12-27 15:30:09
Aptevo Therapeutics Inc. ( APVO ) https://www.aptevotherapeutics.com
5.11USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-98.34%
APVO
SPY
32.66%
-99.96%
APVO
SPY
108.59%
-99.96%
APVO
SPY
302.52%
APVO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1.38
-0.84
0.16
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.06
0.13
0.31
-13.38
0.00
0.04
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-774.17
-11.75
-639.36
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
23.3456
-93.38
-108.67
5.17
Other Earnings and Cash Flow Stats:
Aptevo Therapeutics Inc. ( APVO ) Net Income TTM ($MM) is -23.72
Aptevo Therapeutics Inc. ( APVO ) Operating Income TTM ($MM) is -24.60
Aptevo Therapeutics Inc. ( APVO ) Owners' Earnings Annual ($MM) is 0.00
Aptevo Therapeutics Inc. ( APVO ) Current Price to Owners' Earnings ratio is 0.00
Aptevo Therapeutics Inc. ( APVO ) EBITDA TTM ($MM) is -24.21
Aptevo Therapeutics Inc. ( APVO ) EBITDA Margin is -639.36%
Capital Allocation:
Aptevo Therapeutics Inc. ( APVO ) has paid 0.00 dividends per share and bought back 0.00079499999999999 million shares in the past 12 months
Aptevo Therapeutics Inc. ( APVO ) has reduced its debt by 0.77 million USD in the last 12 months
Capital Structure:
Aptevo Therapeutics Inc. ( APVO ) Interest-bearing Debt ($MM) as of last quarter is 5
Aptevo Therapeutics Inc. ( APVO ) Annual Working Capital Investments ($MM) are 0
Aptevo Therapeutics Inc. ( APVO ) Book Value ($MM) as of last quarter is 4
Aptevo Therapeutics Inc. ( APVO ) Debt/Capital as of last quarter is 125%
Other Balance Sheet Stats:
Aptevo Therapeutics Inc. ( APVO ) has 7 million in cash on hand as of last quarter
Aptevo Therapeutics Inc. ( APVO ) has 5 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Aptevo Therapeutics Inc. ( APVO ) has 0 common shares outstanding as of last quarter
Aptevo Therapeutics Inc. ( APVO ) has 0 million USD of preferred stock value
Academic Scores:
Aptevo Therapeutics Inc. ( APVO ) Altman Z-Score is -26.76 as of last quarter
Aptevo Therapeutics Inc. ( APVO ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Aptevo Therapeutics Inc. ( APVO ) largest shareholder is RENAISSANCE TECHNOLOGIES LLC owning 36575 shares at 0.19 ($MM) value
Lamothe Jeffrey G.(CFO) Bought 11000 shares of Aptevo Therapeutics Inc. ( APVO ) for the amount of $0.00 on 2022-03-04
0.03% of Aptevo Therapeutics Inc. ( APVO ) is held by insiders, and 11.36% is held by institutions
Aptevo Therapeutics Inc. ( APVO ) went public on 2016-07-20
Other Aptevo Therapeutics Inc. ( APVO ) financial metrics:
FCF:-23.30
Unlevered Free Cash Flow:0.00
EPS:-1.93
Operating Margin:-774.17
Gross Profit Margin:-11.75
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-461.63
Beta:5.17
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Aptevo Therapeutics Inc. ( APVO ) :
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.